Login to Your Account



J&J, Orexo in $585M Deal on Preclinical Modulators

By Cormac Sheridan


Wednesday, June 2, 2010
Orexo AB is getting an up-front payment of $10 million and will get another $11.5 million in research funding on the back of an alliance with Johnson & Johnson subsidiaries Ortho-McNeil-Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica NV to develop two of its preclinical programs, which target pathways involved in arachidonic acid metabolism. For good measure, J&J, of New Brunswick, N.J., is throwing an as yet unselected third compound of its own into the mix. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription